inb12b25_20100517.htm
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
Commission File Number
001-31668
NOTIFICATION OF LATE
FILING
| (Check
One): |
o Form
10-K |
o Form
11-K |
o Form
20-F |
x Form
10-Q |
o Form
N-SAR |
For
Period Ending: March 31,
2010
o Transition Report on
Form 10-K o Transition Report on
Form 10-Q
o Transition Report on
Form 20-F o Transition Report on
Form N-SAR
o Transition Report on
Form 11-K
Read the attached instruction sheet
before preparing form. Please print or type.
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
Part
I. Registrant Information
Full name
of registrant: Integrated BioPharma,
Inc.
Former
name if applicable:
Address
of principal executive office (Street and number): 225 Long
Avenue
City,
State and Zip Code: Hillside, New Jersey
07205
Part
II. Rule 12b-25(b) and (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check appropriate box.)
|
|
T (a) The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or
expense;
|
|
|
T (b) The
subject annual report, semi-annual report, transition report on Form 10-K,
20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before
the 15th calendar day following the prescribed due date; or the subject
quarterly report on transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following the prescribed
due date; and
o (c) The accountant's statement or other exhibit required
by Rule 12b-25(c) has been attached is
applicable.
|
Part
III. Narrative
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or
the transition report portion thereof could not be filed within the prescribed
time period. (Attached extra sheets if needed.)
The
Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31,
2010 cannot be filed within the prescribed time period because the Company is
experiencing delays in the collection and compilation of certain information
required to be included in the Form 10-Q. The Company’s Quarterly
Report on Form 10-Q will be filed on or before the fifth calendar day following
the prescribed due date.
Part
IV. Other Information
(1)Name and telephone number of person to
contact in regard to this notification
|
Louis
Goldberg
|
(212)
|
592-1498
|
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
(2)Have all other periodic reports
required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or
Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such
report(s) been filed? If the answer is no, identify
report(s).
T
Yes o No
(3)Is it anticipated that any significant
change in results of operations from the corresponding period for the last
fiscal year will be reflected by the earnings statements to be included in the
subject report or portion thereof?
o
Yes T
No
If so:
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
INTEGRATED BIOPHARMA,
INC.
(Name of registrant as specified in
charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date: May 17,
2010
|
By:
|
s/ Dina L. Masi
|
|
|
|
Name: Dina
L. Masi
|
|
|
|
Title: Chief
Financial Officer & Senior Vice
President
|